Review on AMB-FUBINACA one of synthetic cannabinoids present in Egypt | ||
| Ain Shams Journal of Forensic Medicine and Clinical Toxicology | ||
| Article 9, Volume 39, Issue 2, July 2022, Pages 72-76 PDF (1.21 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ajfm.2022.251215 | ||
| Authors | ||
| Mosab Rashwan1; Maha Hilal1; Hoda Elsayed2; Khaled Mohamed3; Walaa Allam4 | ||
| 1Forensic Medicine & Clinical Toxicology Department, Faculty of Medicine, Sohag University, Sohag, Egypt. | ||
| 2Histology & Cell Biology, Faculty of Medicine, Sohag University, Sohag, Egypt. | ||
| 3Department of Forensic Chemistry, Naif Arab University for Security Sciences, Riyadh, KSA | ||
| 4Forensic Medicine & Clinical Toxicology Department, Faculty of Medicine, Sohag University, Sohag, Egypt | ||
| Abstract | ||
| Background: Synthetic cannabinoids are currently the largest group of new psychoactive substances. Those that have been subjected to legal control are replaced by newer uncontrolled substances, which cause constant and dynamic changes to the drug market. AMB-FUBINACA is one of the recent synthetic cannabinoids appeared globally. In 2018, the official spokesman for the Ministry of Health in Egypt announced that the Strox consists of five types of synthetic cannabinoids which have been added to the Egyptian list of highly addictive and dangerous narcotics. These SCs are; AB-FUBINACA, AMB-FUBINACA, 5F-ADB, AB-CHMINACA, and XLR-11. Aim of the work: To spotlight the toxic effect of AMB-FUBINACA as a new synthetic cannabinoid. Conclusion: AMB-FUBINACA has been the focus of interest by health care professionals, as their use put the health of many humans at risk especially young adults. Received in original form: 24 December 2021 Accepted in a final form: 30 June 2022 | ||
| Keywords | ||
| synthetic cannabinoids; AMB-FUBINACA-Toxicity | ||
|
Statistics Article View: 235 PDF Download: 456 |
||
